High-dose interleukin-2 therapy related adverse events and implications on imaging

High-dose interleukin-2 therapy related adverse events and implications on imaging

High-dose interleukin-2 (HDIL-2) therapy was initially approved by the U.S. Food and Drug Administration for metastatic renal cell carcinoma (mRCC) and metastatic melanoma. IL-2 is able to promote CD8+ T cell and natural killer (NK) cell cytotoxicity to increase tumoricidal activity of the innate im...

Full description

Bibliographic Details
Main Authors: Neal R. Shah, Brandon Declouette, Kianoush Ansari-Gilani, Mohammad S. Alhomoud, Christopher Hoimes, Nikhil H. Ramaiya, Ezgi Güler
Format: Article
Language:English
Published: Galenos Publishing House 2021-09-01
Series:Diagnostic and Interventional Radiology
Online Access: http://www.dirjournal.org/archives/archive-detail/article-preview/high-dose-interleukin-2-therapy-related-adverse-ev/54057

Internet

http://www.dirjournal.org/archives/archive-detail/article-preview/high-dose-interleukin-2-therapy-related-adverse-ev/54057

Similar Items